Solid-phase synthesis of oxaliplatin-TAT peptide bioconjugates

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Drug Delivery

Background:

• Platinum-based drugs like oxaliplatin are vital in cancer therapy, particularly for colorectal carcinoma.
• Therapeutic efficacy is often limited by poor accumulation of platinum drugs within cancer cells.
• Cell-penetrating peptides (CPPs), such as TAT peptides, facilitate cellular membrane transport and can serve as drug delivery vectors.

Purpose of the Study:

• To conjugate a TAT peptide fragment to a platinum(IV) analog of oxaliplatin.
• To create a novel platinum-based conjugate for enhanced cancer cell membrane penetration.
• To evaluate the anti-cancer activity of the novel conjugates.

Main Methods:

• Solid-phase peptide synthesis was employed for conjugate formation.
• The platinum complex was coupled to the TAT peptide fragment.
• Purification and characterization involved preparative and analytical HPLC, ESI-MS, and (1)H NMR spectroscopy.

Main Results:

• Mono- and difunctionalized platinum-peptide conjugates were successfully synthesized and characterized.
• Both conjugates demonstrated anti-cancer activity in the low micromolar range against CH1 and SW480 human cancer cells.
• The targeted conjugates achieved equivalent anti-cancer effects at significantly lower concentrations compared to untargeted analogs.

Conclusions:

• Conjugation of TAT peptides to oxaliplatin analogs effectively enhances drug delivery into cancer cells.
• This novel approach offers a promising strategy for improving the efficacy of platinum-based cancer therapies.
• Reduced drug concentrations required for therapeutic effect may lead to decreased systemic toxicity.